Our findings propose that MiR206‐3p sponge represents an innovative therapeutic strategy to attenuate AAA progression and rupture risk, primarily through the suppression of the CXCL12/CXCR4 signalling pathway. Here, CXCR4 is linked to triple-A syndrome.